Truist cuts target to USD 51.00 for Boston Scientific stock

Published on 10/15/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results arrive on October 28, 2026. Boston Scientific stock costs EUR 38.87 on October 15, 2026, 0.80 percent above the October 14 Frankfurt close.

Analyst target and earnings date

Truist lowered its Boston Scientific target from USD 57.00 to USD 51.00 on October 14, 2026.
MarketBeat lists a consensus revenue estimate of USD 5.12 billion for the third quarter of 2026.
Boston Scientific stock costs EUR 38.87 at Lang & Schwarz on October 15, 2026 at 3:00 p.m. CEST, 0.80 percent above the Frankfurt close of October 14, 2026.
The next earnings report is scheduled for October 28, 2026, before the US market opens.

Flatlay auf Marmor mit Aktienzertifikat, ISIN-Karte US1011371077, Bürogebäude-Miniatur und Schlüsseln — Boston Properties US1011371077 symbolisiert durch Aktienzertifikat, ISIN-Karte und Bürogebäude-Modell auf weißem Marmor, Illustration mit AI erstellt.

Truist lowered its Boston Scientific target from USD 57.00 to USD 51.00 on October 14, 2026, while keeping a Buy rating, as Markets Insider reported. Against the last US quote of USD 43.00 on October 14, 2026, the new target stood 18.60 percent higher. Boston Scientific was trading at EUR 38.87 at Lang & Schwarz on October 15, 2026 at 3:00 p.m. CEST, 0.80 percent above the Frankfurt close of October 14, 2026 at EUR 38.56.

October 28 sets the next test

Boston Scientific is scheduled to report third-quarter 2026 results before the US market opens on October 28, 2026. The conference call is scheduled for 8:00 a.m. ET, according to MarketBeat. The page lists consensus expectations of USD 0.75 earnings per share and USD 5.12 billion in revenue for the quarter.

Price sits above its Frankfurt close

The euro quotation is modestly higher than its German-market comparison, while the US listing was last at USD 43.00 on October 14, 2026 at 4:00 p.m. ET. Finance figures place Boston Scientific's market capitalization at USD 62.4 billion and its price-to-earnings ratio at 17.48 as of October 14, 2026. The 52-week range was USD 41.39 to USD 105.65 on the same date.

Comparison with peers

Boston Scientific: plus 0.80 percent, P/E 17.48, market capitalization USD 62.4 billion.
Medtronic (NYSE, USD): plus 1.31 percent, P/E 23.21, market capitalization USD 120.5 billion.
Edwards Lifesciences (NYSE, USD): plus 1.38 percent, P/E 49.68, market capitalization USD 49.8 billion.

Valuation and reporting date

Boston Scientific's valuation is below the multiples of both named peers, although the companies differ in growth profiles and product mix. Its next scheduled report on October 28, 2026 gives investors a near-term date for testing the USD 51.00 Truist target against operating results. Boston Scientific is listed on the NYSE under BSX and operates in medical devices, with products spanning cardiovascular care, electrophysiology, neuromodulation, endoscopy and urology.

Stock position in euros

The Frankfurt comparison provides a dated German-market reference for the euro quotation. The primary US quote was last at USD 43.00 on October 14, 2026, while the Lang & Schwarz price was higher in euro terms on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.